P1 Pratia Oncology Expands Its Research Network into Spain through New Clinical Site in Madrid

P1 Pratia Oncology Expands into Europe

P1 Pratia Oncology, a prominent network specializing in community-based oncology research, has recently made a significant move by expanding its operations into Europe. This expansion is marked by the establishment of the OC España clinical research site located at Hospital Universitario Vithas Madrid La Milagrosa. This site not only strengthens P1's international presence but is also noteworthy as it constitutes the network's first independent Phase I oncology unit.

The shift into the European market underscores P1's commitment to enhancing access to early-phase clinical trials, which are critical for developing new oncological treatments. By leveraging partnerships with established oncology practices and institutions, P1 provides essential infrastructure, operational expertise, and streamlined support aimed at facilitating complex early-phase oncology trials.

A Dedicated Focus on Early-Phase Trials

With a focus on early-phase clinical research, the Madrid site is designed exclusively for clinical trials, particularly first-in-human studies. This strategic setup differs from conventional oncology practices that often integrate research into their patient care settings. Instead, OC España has been purposefully constructed to meet the specialized requirements inherent in early-phase oncology research. This synergy with the Oncology Vithas Institute enhances the site’s capabilities in managing intricate clinical studies.

Dr. Julio Peguero, President and Chairman of P1 Pratia Oncology, emphasizes that the Madrid site solidifies their mission to bolster early-phase oncology trials while expanding their role as a global drug development partner. The emphasis on collaborating with established clinical practices such as those in Spain illustrates P1's commitment to bringing innovative treatment options to patients within their local communities.

Expanding Collaborative Efforts

The installation of OC España is an avenue for enhancing P1’s existing collaboration dynamics with proven U.S. practices, ensuring that international partnerships enhance clinical trial capabilities and accelerate patient recruitment. The Madrid site extends the reach of OC's established research expertise, creating a bridge that connects U.S. operations with European studies. Dr. Begoña de las Heras, CEO and Medical Director of OC España, notes that this expansion is pivotal for integrating clinical expertise and community dedication within their research network.

The Vision for Future Research

P1 Pratia's expansion into Madrid marks an exciting chapter, amplifying their existing network while contributing to a comprehensive, interconnected system of oncology research sites. This network not only fosters teamwork across geographical boundaries but also equips experienced oncology teams with the means to conduct advanced and complex clinical trials.

Scott Schliebner, CEO of P1 Pratia Oncology, expresses enthusiasm about the new chapter. He states that this extension into Europe significantly aligns with their strategy of creating a connected network that possesses the requisite expertise and infrastructure for advancing comprehensive clinical trials, enhancing patient access to groundbreaking early-phase research.

P1 Pratia Oncology is part of the Humaneva Group and operates as the U.S. oncology research network within Pratia. They are dedicated to expanding access to clinical research, finding innovative solutions, and establishing efficiencies in trial operations. Their strategic partnerships position them favorably as a leader in integrating research with everyday healthcare practices.

For more insights and updates about P1 Pratia Oncology's initiatives, visit P1 Trials and explore Pratia's offerings.